STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more

Biogen and Denali Therapeutics' experimental Parkinson's drug targeting the LRRK2 protein failed to slow disease progression in a clinical trial, dealing a setback to a promising scientific approach. Separately, Genentech is offering researchers up to $125,000 in grants to produce papers on pharmaceutical pricing policies and innovation, raising questions about the independence of such research.